N-doped graphitic carbon-improved Co–MoO3 catalysts on ordered mesoporous SBA-15 for chemoselective reduction of nitroarenes
作者:Haigen Huang、Xiangcheng Liang、Xueguang Wang、Yao Sheng、Chenju Chen、Xiujing Zou、Xionggang Lu
DOI:10.1016/j.apcata.2018.04.024
日期:2018.6
promoting the dissociation of hydrazine molecule into the active H* species for the reduction of nitro groups. After the seventh cycle for reduction of 4-methoxylnitrobenzene, the 2%Co–MoO3/[email protected] showed little change in catalytic performance, textural properties, size and dispersion of metal species and valencestates of elements, indicating high stability and recyclability.
Preparation of Well-Ordered Mesoporous-Silica-Supported Ruthenium Nanoparticles for Highly Selective Reduction of Functionalized Nitroarenes through Transfer Hydrogenation
作者:Ning Wei、Xiujing Zou、Haigen Huang、Xueguang Wang、Weizhong Ding、Xionggang Lu
DOI:10.1002/ejoc.201701228
日期:2018.1.17
Ru nanoparticles supported on MCM‐41‐type mesoporous silica (Ru/OMS‐IL) is used as a catalyst for the selectivehydrogenation of nitroarenes. Ru/OMS‐IL exhibits high activity and chemoselectivity for the reduction of various nitroarenesundermildconditions. The Ru/OMS‐IL catalyst can be recycled over at least six runs without any observable loss in catalytic performance.
Substituted morpholine and thiomorpholine derivatives
申请人:Tornoe Wenzel Christian
公开号:US20060167248A1
公开(公告)日:2006-07-27
The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
本发明涉及通式I的吗啡啶和硫代吗啡啶衍生物或其药学上可接受的盐及其用途。
Methods of using substituted morpholine derivatives
申请人:Tornøe Christian Wenzel
公开号:US20100063033A1
公开(公告)日:2010-03-11
The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
本发明涉及一般式I的吗啡啶和硫代吗啡啶衍生物或其药学上可接受的盐以及它们的用途。
SUBSTITUTED THIOMORPHOLINE DERIVATIVES
申请人:Wenzel Tornøe Christian
公开号:US20110294787A1
公开(公告)日:2011-12-01
The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.